SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : wla(warner lambert)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony Wong who wrote (642)3/28/1999 12:01:00 PM
From: Captain Jack  Read Replies (1) of 942
 
Tony--- even more GOOD news..

Depressing news for Lilly's Prozac . . .

NEW YORK (CBS.MW) -- Merrill Lynch is
singing the blues about Prozac, cutting its revenue
expectations from Eli Lilly's (LLY) anti-depressant on concerns rival drug
Celexa threatens to take a 19 percent market share within three years.
Sales of Celexa, the anti-depressant developed by Forest Labs (FRX)
and co-marketed by Warner-Lambert (WLA), could exceed $1 billion in
2003, Merrill analysts said. Merrill Lynch, which commissioned a
research firm to get doctor feedback, reportedly found that Celexa has
fewer serious side effects, including incidences of sexual dysfunction and
drug interactions.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext